Patent ID: 11885817
Assignee: COGNIZANCE BIOMARKERS, LLC
Field: Measurement (Instruments)
Classification: CPC G  A  C | IPC C  G

Claim 0:
1. A method of treating epilepsy in a patient in need of epilepsy treatment, the method comprising:
contacting one or more blood samples obtained from the patient with one or more antibodies targeting one or more biomarkers selected from the group consisting of thymus and activation-regulated chemokine (TARC), interleukin (IL)-7, monocyte chemotactic protein (MCP)-4, macrophage colony-stimulating factor (M-CSF), MCP-2, IL-8, macrophage inflammatory protein (MIP)-1B, macrophage migration inhibitory factor (MIF), Eotaxin, MIP-5, IL-15, Eotaxin-2, TNF-RI, interferon gamma-induced protein 10 (IP-10), granulocyte macrophage colony stimulating factor (GM-CSF), IL-12p70, and IL-1B;
measuring the concentrations of the one or more biomarkers in the one or more blood samples;
comparing the concentrations of the one or more biomarkers in the one or more blood samples to the concentration of the one or more biomarkers in one or more controls; and
treating the patient for epilepsy by administering to the patient one or more therapeutic agents selected from the group consisting of phenytoin, carbamazepine, oxcarbazepine, zonisamide, lamotrigine, and pharmaceutically acceptable salts and prodrugs thereof;
wherein the patient is in need of epilepsy treatment when the concentrations of the one or more biomarkers are elevated in the one or more blood samples relative to the one or more controls.